New automated VPT systems for topical drug performance testing
The MedStat-HT and MedFlux-HT help to de-risk development programs and shorten development timelines.
MedPharm has launched two automated testing services, MedStat-HT and MedFlux-HT to de-risk clients' development programs and shorten development timelines. Both pieces of equipment incorporate design features that provide significant improvements over commercially available systems.
MedFlux-HT is an automated system of 32 flow-through diffusion cells for measuring the in vitro permeation and penetration of drugs into and through human skin (IVPT). It can also be set up with other tissues determined by the medicine’s target site (e.g., mucosal, buccal, etc.). The system has been uniquely designed to provide local clearance of the tissue to mimic the clinical setting and to maximise sink conditions without the addition of solvents when studying lipophilic compounds in static cells.
Another key design improvement is the use of a high-throughput collection enabling reduction in sample collection, set-up time, and processing which can be further coupled with liquid handlers and automated sample managers. MedPharm use MedFlux-HT® as a key tool in topical formulation development, and optimisation. Significant benefits of this new system include reduction in sample variation, system artefacts, and experimental time to further de-risk topical formulation development prior to clinical trials. The use of MedFlux-HT has been important in the support of patent claims, substantiation of marketing claims for OTC products, new chemical entity development, and development of generic products.
MedStat-HT is an automated system of 24 vertical diffusion cells (VDC) more commonly known as ‘Franz’ or ‘static’ cells for measuring the in vitro release of drug from topical medicines across synthetic membranes (IVRT). Unique design features along with automated collection provide significant reduction in variation associated with sampling and fluidics compared with manually operated VDC systems. The key benefits of the new system are its ability to better characterise formulation drug release properties for potential patent claim support (formulation optimisation and comparison, and potential product quality and stability specifications) with a reduction in experimental time and less variability.
"MedPharm is continuing to develop innovative solutions to help our clients further de-risk their topical development programs and reduce development timelines," commented Jon Lenn, MedPharm’s Vice President of US Operations. He added: "MedStat-HT and MedFlux-HT greatly improve the efficiency of data collection and decrease variations seen with conventional systems for IVRT and IVPT, so clients and their investors gain confidence in the data generated and ultimately get to the market sooner."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance